ABIVAX to Present at Upcoming Investors Conferences

Regulatory News:

ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today announced that senior management of ABIVAX will present and host investor meetings at the following upcoming investor events:

• German Equity Forum from November 21^st to 23^rd at the Sheraton Frankfurt Airport Hotel and Conference Center in Frankfurt am Main (Germany). Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX will present on Tuesday, November 22^nd at 3:00pm – 3:30pm CET in Room Oslo.

To schedule investor or media meetings with ABIVAX management at the German Equity Forum, please contact: solveigh.maehler@mc-services.eu.

• 28^th Annual Piper Jaffray Healthcare Conference from November 29^th to 30^th at the Lotte New York Palace Hotel in New York, NY. Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX will participate in a fireside chat on Tuesday, November 29^th, from 4:30 to 4:55 PM EST.

To schedule investor or media meetings with ABIVAX management at the Piper Jaffray Healthcare Conference, please contact: chris@lifesciadvisors.com

About ABIVAX (www.abivax.com)

ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. ABIVAX leverages three technology platforms for drug discovery: an anti-viral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase II clinical trials and is a first-in-class oral small anti-viral molecule which blocks HIV replication through a unique mechanism of action. In addition, ABIVAX is advancing multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue) as well as an immune enhancer, and several of these compounds are planned to enter clinical development within the next 18 months. A recently updated corporate presentation, which includes a timeline for the company’s anticipated news flow, is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

View source version on businesswire.com: http://www.businesswire.com/news/home/20161115006451/en/